Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression | Synapse

June 29, 2017Open Access

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and NCT01844505 (CheckMate 067).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Long et al. (Thu,) studied this question.

synapsesocial.com/papers/69d92573e0d31bb747835ee3 https://doi.org/https://doi.org/10.1001/jamaoncol.2017.1588

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression2016 · 178 citations
2The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.2008 · 166 citations
3Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.2015 · 100 citations
4Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.2015 · 20 citations
5Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.2016 · 16 citations